MX378799B - Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. - Google Patents

Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.

Info

Publication number
MX378799B
MX378799B MX2018013969A MX2018013969A MX378799B MX 378799 B MX378799 B MX 378799B MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 378799 B MX378799 B MX 378799B
Authority
MX
Mexico
Prior art keywords
combination
pure
receptor antagonist
nmda
receptor
Prior art date
Application number
MX2018013969A
Other languages
English (en)
Other versions
MX2018013969A (es
Inventor
Anil Karbhari Shinde
Gopinadh Bhyrapuneni
Pradeep Jayarajan
Ramakrishna Nirogi
Ramasastri Kambhampati
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2018013969A publication Critical patent/MX2018013969A/es
Publication of MX378799B publication Critical patent/MX378799B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al antagonista del receptor 5-HT6 puro o la sal o sales farmacéuticamente aceptables del mismo en combinación o como complementario de un antagonista del receptor NMDA y a su uso en el tratamiento de trastornos cognitivos. La invención también se refiere a la composición farmacéutica que contiene dicha combinación.
MX2018013969A 2016-05-18 2016-08-03 Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. MX378799B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641017203 2016-05-18
PCT/IB2016/054674 WO2017199072A1 (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist

Publications (2)

Publication Number Publication Date
MX2018013969A MX2018013969A (es) 2019-03-21
MX378799B true MX378799B (es) 2025-03-11

Family

ID=56940099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013969A MX378799B (es) 2016-05-18 2016-08-03 Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.

Country Status (19)

Country Link
US (1) US11116764B2 (es)
EP (1) EP3458040B1 (es)
JP (1) JP6606298B2 (es)
KR (1) KR102023748B1 (es)
CN (1) CN109069449A (es)
AU (1) AU2016407428B2 (es)
BR (1) BR112018073396A2 (es)
CA (1) CA3023828C (es)
DK (1) DK3458040T3 (es)
EA (1) EA036301B1 (es)
HK (1) HK1258023A1 (es)
HR (1) HRP20210640T1 (es)
HU (1) HUE055083T2 (es)
IL (1) IL262816B (es)
MX (1) MX378799B (es)
NZ (1) NZ747778A (es)
SG (1) SG11201809725TA (es)
WO (1) WO2017199072A1 (es)
ZA (1) ZA201807311B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6959371B2 (ja) * 2017-07-03 2021-11-02 スヴェン・ライフ・サイエンシーズ・リミテッドＳｕｖｅｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
EP4069232B1 (en) * 2019-12-02 2025-12-24 Suven Life Sciences Limited Masupirdine for treating behavioral and psychological symptoms in dementia
ES3036880T3 (en) 2019-12-02 2025-09-25 Suven Life Sciences Ltd Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005701A (es) * 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil indoles sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
EA009367B1 (ru) * 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
CN105814020B (zh) * 2013-12-02 2018-04-17 苏文生命科学有限公司 用于大规模生产1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的方法
HRP20190446T1 (hr) * 2014-08-16 2019-05-03 Suven Life Sciences Limited Aktivni metabolit 1-[(2-bromofenil) sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilat monohidrata i dimezilat dihidrat sol aktivnog metabolita

Also Published As

Publication number Publication date
WO2017199072A1 (en) 2017-11-23
NZ747778A (en) 2020-03-27
JP6606298B2 (ja) 2019-11-13
CA3023828A1 (en) 2017-11-23
KR102023748B1 (ko) 2019-09-20
JP2019516696A (ja) 2019-06-20
DK3458040T3 (da) 2021-05-03
ZA201807311B (en) 2020-01-29
HRP20210640T1 (hr) 2021-06-25
CA3023828C (en) 2019-08-27
US11116764B2 (en) 2021-09-14
KR20180136566A (ko) 2018-12-24
MX2018013969A (es) 2019-03-21
EA201892583A1 (ru) 2019-04-30
HK1258023A1 (zh) 2019-11-01
IL262816A (en) 2018-12-31
EA036301B1 (ru) 2020-10-23
EP3458040A1 (en) 2019-03-27
HUE055083T2 (hu) 2021-10-28
EP3458040B1 (en) 2021-01-27
CN109069449A (zh) 2018-12-21
US20190175586A1 (en) 2019-06-13
AU2016407428A1 (en) 2018-11-29
IL262816B (en) 2020-05-31
BR112018073396A2 (pt) 2019-03-19
SG11201809725TA (en) 2018-12-28
AU2016407428B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
MX387700B (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
MX2017001452A (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglur2).
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
MX2017001454A (es) Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-ona y su uso como moduladores alostericos negativos de receptores de glutamato metabotropico subtipo 2 (mglu2r2).
JO3601B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CY1123013T1 (el) Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX378799B (es) Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
MY189372A (en) Indole derivatives
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
MX387920B (es) Peptidos antagonistas de prgc.
MX374114B (es) Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
MX377517B (es) Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda.
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
MX386462B (es) Composiciones farmaceuticas de antagonista del 5-ht6.
MX394259B (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)